<DOC>
	<DOCNO>NCT02465502</DOCNO>
	<brief_summary>To determine efficacy ( measure progression-free survival [ PFS ] rate 8 week ) regorafenib subject metastatic colorectal cancer ( CRC ) whose disease refractory standard therapy never expose antiangiogenic therapy .</brief_summary>
	<brief_title>Regorafenib Subjects With Antiangiogenic-naive Chemotherapy-refractory Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Male female subject ≥18 year age ; Histological cytological confirmation adenocarcinoma colon or/and rectum ; Subjects metastatic colorectal cancer ( CRC ) whose disease progress intolerant standard chemotherapy base fluoropyrimidine , oxaliplatin , irinotecan , antiEGFR therapy RAS wildtype . This progression must within 4 month follow last administration standard therapy . Measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion , Version 1.1 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate bonemarrow , liver , renal function Women childbearing potential men must agree use adequate contraception sexually active study least 8 week last study drug administration . Prior treatment antiangiogenic agent ; Congestive heart failure New York Heart Association ( NYHA ) class 2 worse ; Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) . Myocardial infarction le 6 month start study drug ; Cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) Uncontrolled hypertension ( systolic blood pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg despite optimal medical management ) ; Ongoing acute chronic infection ( &gt; Grade 2 NCICTCAE v 4.03 ) ; Arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism ( except adequately treat catheterrelated venous thrombosis occur one month start study medication ) event within 6 month study enrollment . Subjects treat lowweight heparin allow participate long dose limited prophylactic use . Any history currently know brain metastasis ( head CT/MRI perform screening period brain metastasis suspect ) Previous concurrent cancer distinct primary site histology colorectal cancer within 5 year study entry , except curatively treated cervical cancer situ , situ ductal breast cancer , nonmelanoma skin cancer superficial bladder tumor ; Last chemotherapy dose anticancer therapy administer less 4 week start study treatment ; Use therapeutic anticoagulation ; Proteinuria &gt; 3.5 g/24 hour measure urine proteincreatinine ratio random urine sample ( Grade 3 , NCICTCAE v 4.03 ) urinalysis screen result . If medical history proteinuria , previous urinalysis result consider and/or perform least 2 result separate least 2 week available ; History interstitial lung disease ongoing sign symptoms time informed consent ; Nonhealing wound , nonhealing ulcer , nonhealing bone fracture ; Subjects evidence history bleed diathesis , irrespective severity ; Any hemorrhage bleeding event ≥ Grade 3 NCICTCAE v 4.03 within 4 week prior start study medication ; Known history human immunodeficiency virus ( HIV ) infection ; History active hepatitis B C , chronic hepatitis B C require treatment antiviral therapy ; Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Regorafenib</keyword>
</DOC>